Medical oncology and pancreatic cancer: what the radiologist needs to know

被引:0
作者
David R. Fogelman
Gauri Varadhachary
机构
[1] University of Texas/MD Anderson Cancer Center,
来源
Abdominal Radiology | 2018年 / 43卷
关键词
Pancreatic adenocarcinoma; Borderline resectable; Metastatic; Locally advanced; Staging; Treatment;
D O I
暂无
中图分类号
学科分类号
摘要
The majority of PCs present as advanced disease, and treatment goals are for prolongation of life and palliation of the symptoms. Oncologists rely on our radiology colleagues to provide information on the extent of disease and the effectiveness of our treatment. The stakes rise in those patients where the disease has seemingly not spread and who might be treated with a goal of cure. For this subset of patients, medical oncologists and surgeons require as precise a radiologic description as possible in order to most accurately characterize the extent of the disease, in turn informing us as to the likelihood of a successful surgery and potential cure. In this paper, we review the fine points of imaging that distinguish resectable from borderline or unresectable patients, explain the principles of neoadjuvant and adjuvant therapy for pancreatic cancer, highlight some of the novel therapies now being pioneered in pancreatic cancer, and review radiologic features important for palliative care in patients with these tumors.
引用
收藏
页码:383 / 392
页数:9
相关论文
共 159 条
[1]  
Siegel RL(2017)Cancer statistics, 2017 CA Cancer J Clin 67 7-30
[2]  
Miller KD(2014)Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States Cancer Res 74 2913-2921
[3]  
Jemal A(2013)Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial JAMA 310 1473-1481
[4]  
Rahib L(2001)Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial Ann Surg 234 758-768
[5]  
Smith BD(2000)Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators J Gastrointest Surg 4 567-579
[6]  
Aizenberg R(2003)Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single-institution experience Pancreas 26 243-249
[7]  
Oettle H(2009)Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement Ann Surg Oncol 16 1727-1733
[8]  
Neuhaus P(2006)Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy Ann Surg Oncol 13 1035-1046
[9]  
Hochhaus A(2014)Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic association Gastroenterology 146 291 e1-304 e1
[10]  
Neoptolemos JP(2013)FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis World J Gastroenterol 19 4808-4817